Intellectual Property Landscape of Nanoparticle Drug Delivery Patents
COVID-19 vaccines sparked a patent race that reshaped nanoparticle drug delivery.
Priya Subramaniam
Delivery Platform Review — Page 2
Translational Research
Translating Academic Nanoparticle IP Into a Drug Development Program
Nasal nanoparticles could deliver GLP-1 to the brain more safely.
Nanoparticle Platforms Engineering Peptide Blood-Brain Barrier Crossing
Nanoparticles hijack the brain barrier's own transport systems to deliver peptide drugs.
Cecilia Brandt-Kowalski
More From Delivery Platform Review
Nanoparticle Scale-Up Challenges From Lab Bench to GMP Manufacturing
Particle properties shift unpredictably when equipment scales up.
Marcus Oyelaran
Regulatory Pathway for Intranasal CNS Drug Products at FDA
FDA lacks unified standards for proving drugs reach the brain via nasal delivery.
Cecilia Brandt-Kowalski
Bioavailability Benchmarks for Intranasal Peptide Formulations
Plasma bioavailability fails to measure what intranasal brain-targeted peptides actually achieve.
Marcus Oyelaran
Nose-to-Brain Delivery for CNS-Active Peptides in Preclinical Models
Nasal delivery bypasses the blood-brain barrier for peptides that can't cross it systemically.
Priya Subramaniam
Subcutaneous Auto-Injector Design and Its Adherence Ceiling
The handheld auto-injector hits its limits with larger, thicker drugs.
Priya Subramaniam
Oral GLP-1 Delivery Platforms and the Bioavailability Problem
Oral GLP-1s work around fundamental biology by accepting near-total losses at the gut barrier.
Daniel Ngô
Weight Loss Versus Metabolic Benefit in GLP-1 Therapy
The drugs' real power lies in tissue-specific effects that exist independent of weight loss.
Daniel Ngô
GLP-1 Receptor Agonists in Type 1 Diabetes and Non-Obesity Indications
Trial data shows GLP-1 drugs reduce heart risk in type 1 diabetes.
Cecilia Brandt-Kowalski
GLP-1 Receptor Distribution in the Brain and CNS Pharmacology
Brain GLP-1 receptors span reward, appetite, and cognition circuitry, reshaping how the drugs work.
Cecilia Brandt-Kowalski